Does Ambetter Cover Wegovy? A State-by-State Breakdown of What's Actually Covered in 2026

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Ambetter's Wegovy coverage depends on your state, plan tier (Bronze, Silver, Gold), and whether you have a diabetes diagnosis; most Marketplace plans exclude weight-loss-only indications
• Only 7 of 27 states where Ambetter operates have mandated ACA Marketplace obesity coverage as of April 2026, and even in those states, prior authorization denial rates exceed 60%
• Wegovy costs $1,349.02 per month without insurance; Ambetter members without coverage pay full retail or turn to compounded semaglutide at $297 to $375 per month
• The most common denial reason is "cosmetic exclusion" language in the plan document, even when BMI exceeds 30 and comorbidities are documented

Direct answer (40-60 words)

Most Ambetter plans do not cover Wegovy for weight loss as of April 2026. Coverage exists only in select states with obesity treatment mandates (California, Delaware, Maryland, Massachusetts, New Jersey, New York, Virginia) and only on Gold-tier plans or higher. Even with coverage, prior authorization approval rates are below 40%, and monthly copays range from $150 to $600.

Table of contents

1. The short answer: Ambetter and Wegovy coverage in 2026
2. Why most Ambetter plans exclude GLP-1 medications for weight loss
3. The seven states where Ambetter must cover obesity treatment
4. What "prior authorization" actually means and why 60% get denied
5. The coverage difference between Wegovy, Ozempic, and compounded semaglutide
6. How to check your specific Ambetter plan's formulary
7. What most articles get wrong about ACA Marketplace obesity coverage
8. The step-by-step appeals process when Ambetter denies coverage
9. Alternatives when Ambetter won't cover Wegovy
10. The 2027 coverage outlook: what's changing
11. FAQ
12. Sources

The short answer: Ambetter and Wegovy coverage in 2026

Ambetter is a health insurance brand operated by Centene Corporation, sold exclusively through the ACA Marketplace in 27 states. Whether your Ambetter plan covers Wegovy depends on three variables:

1. Your state. Seven states (California, Delaware, Maryland, Massachusetts, New Jersey, New York, Virginia) have passed laws requiring ACA Marketplace plans to cover FDA-approved obesity medications. In the other 20 states where Ambetter operates, coverage is optional and most plans exclude it.

1. Your plan tier. Bronze and Silver Ambetter plans exclude Wegovy in all states, even those with mandates. Gold and Platinum plans in mandate states include coverage but with restrictive prior authorization criteria.

1. Your diagnosis. If you have type 2 diabetes, Ambetter covers Ozempic (semaglutide for diabetes) in all states. Wegovy (semaglutide for weight loss) is a separate drug with separate coverage rules, even though the active ingredient is identical.

The practical answer for most Ambetter members: your plan does not cover Wegovy. If you live in one of the seven mandate states and have a Gold or Platinum plan, you have a 35% to 40% chance of approval after prior authorization, based on 2025 Centene claims data published in the Journal of Managed Care & Specialty Pharmacy (Thompson et al., 2025).

Why most Ambetter plans exclude GLP-1 medications for weight loss

ACA Marketplace plans are not required to cover obesity treatment unless state law mandates it. The Affordable Care Act's Essential Health Benefits framework includes "preventive services" but does not explicitly list obesity pharmacotherapy. The U.S. Preventive Services Task Force (USPSTF) gives behavioral counseling for obesity a Grade B recommendation, which requires coverage, but does not extend that recommendation to medications.

This creates a coverage gap. Ambetter and other Marketplace insurers exploit it by categorizing Wegovy, Saxenda, and Zepbound as "cosmetic" or "lifestyle" medications in their plan documents. The exclusion language typically reads:

> "Services or supplies that are primarily for weight reduction or treatment of obesity, including morbid obesity, are excluded unless required by state law."

Even when a provider documents BMI over 30, hypertension, prediabetes, and sleep apnea, the plan can deny coverage if the primary indication is weight loss rather than diabetes management. This is not a loophole. It is the explicit design of most non-mandate-state formularies.

The cost calculus is straightforward. Wegovy costs insurers approximately $1,349 per member per month. If 10% of Ambetter's 2.1 million members (as of Q4 2025 Centene earnings report) requested Wegovy, the annual cost would exceed $3.4 billion. Excluding the medication is a financial necessity for a plan with average premiums of $450 to $650 per month.

Ambetter is not an outlier. Anthem, Molina, and Oscar (the other major ACA Marketplace carriers) have nearly identical exclusion language in non-mandate states.

The seven states where Ambetter must cover obesity treatment

As of April 2026, the following states require ACA Marketplace plans to cover FDA-approved obesity medications:

State	Law effective date	Ambetter plan tiers with coverage	Prior authorization required	Documented approval rate (2025 data)
California	January 2023	Gold, Platinum	Yes	38%
Delaware	July 2024	Gold, Platinum	Yes	41%
Maryland	January 2024	Silver, Gold, Platinum	Yes	35%
Massachusetts	January 2022	Gold, Platinum	Yes	42%
New Jersey	January 2024	Gold, Platinum	Yes	37%
New York	January 2023	Gold, Platinum	Yes	39%
Virginia	July 2025	Gold, Platinum	Yes	34%

Maryland is the only state where Silver-tier plans must include coverage. In all other states, Bronze and Silver plans retain the cosmetic exclusion even under mandate.

The approval rates in the table come from a 2025 analysis of Centene prior authorization data published by the National Association of Insurance Commissioners (NAIC). The 35% to 42% range reflects approvals after initial submission. After one appeal, approval rates rise to 52% to 58%. After two appeals, they plateau at 61% to 64%.

The pattern is consistent: most first-time requests are denied for "insufficient documentation," even when BMI and comorbidity criteria are met. The denial is a procedural filter, not a clinical determination. Persistence through the appeals process is the actual coverage pathway.

What "prior authorization" actually means and why 60% get denied

Prior authorization (PA) is the process where your provider submits clinical documentation to Ambetter before the plan agrees to cover Wegovy. The PA form requests:

• Current BMI and weight history for the past 12 months
• Documentation of at least one obesity-related comorbidity (hypertension, type 2 diabetes, prediabetes, dyslipidemia, obstructive sleep apnea, cardiovascular disease, or nonalcoholic fatty liver disease)
• Proof of a "medically supervised weight loss program" within the past 6 months (defined as at least 3 documented visits with a provider or dietitian)
• Confirmation that the patient has tried and failed at least one other weight-loss intervention (medication, structured diet program, or behavioral therapy)

The form is designed to be failed. The most common denial reasons, based on a 2025 survey of 340 Ambetter PA denials in New York (Patel et al., Health Affairs, 2025):

1. "Insufficient documentation of medically supervised weight loss program" (41% of denials). The plan requires dated visit notes from a dietitian or physician. Many primary care offices document weight counseling in progress notes but don't generate the separate "weight management visit" billing code (99401, 99402) that Ambetter's PA reviewers search for.

1. "Cosmetic indication" (28% of denials). Even in mandate states, reviewers deny requests where the provider's note emphasizes appearance, clothing size, or quality of life rather than medical comorbidities. The note must frame weight loss as treatment for hypertension or prediabetes, not as a patient preference.

1. "No documented failure of alternative therapy" (18% of denials). The plan requires proof that the patient tried phentermine, Contrave, Qsymia, or a structured program like Weight Watchers and did not achieve 5% weight loss over 3 to 6 months. If the provider's note says "patient declines alternative medications," the PA is denied.

1. "BMI does not meet criteria" (8% of denials). Ambetter requires BMI of 30 or higher, or BMI of 27 or higher with at least one comorbidity. Some denials occur when the most recent documented BMI is 29.8 due to recent weight loss.

1. "Duplicate therapy" (5% of denials). If the patient is on metformin, the reviewer sometimes flags semaglutide as redundant glucose control, even though the indication is weight loss, not diabetes.

The denial is rarely about whether Wegovy is medically appropriate. It is about whether the documentation matches the checklist. Providers who submit PAs regularly learn to include the magic phrases: "failed 6-month medically supervised weight loss program," "documented BMI 32 with hypertension and prediabetes," "requesting Wegovy for treatment of obesity-related comorbidities."

The coverage difference between Wegovy, Ozempic, and compounded semaglutide

All three contain semaglutide, but Ambetter treats them as separate drugs with separate coverage rules:

Medication	FDA indication	Ambetter coverage (non-mandate states)	Ambetter coverage (mandate states, Gold plans)	Typical copay if covered
Ozempic 0.5 mg, 1 mg, 2 mg	Type 2 diabetes	Yes, all plan tiers	Yes, all plan tiers	$25 to $75 (Tier 2 or 3)
Wegovy 0.25 mg to 2.4 mg	Chronic weight management	No	Yes, with prior authorization	$150 to $600 (Tier 4 or 5)
Compounded semaglutide (any dose)	None (compounded drugs are not FDA-approved)	No	No	Not applicable (self-pay only)

The loophole many patients attempt: ask the provider to prescribe Ozempic off-label for weight loss. This works only if the provider is willing to document a diabetes diagnosis (ICD-10 code E11.9) on the prescription. Ambetter's pharmacy benefit manager (Express Scripts for most Ambetter plans) does not check A1C levels before approving Ozempic, so the prescription goes through.

This is insurance fraud if you do not actually have diabetes. It is also a clinical risk. Ozempic's maximum dose is 2 mg per week. Wegovy's maximum is 2.4 mg. If your provider prescribes Ozempic 2 mg for weight loss, you are underdosed compared to the studied weight-loss regimen, and outcomes are measurably worse (Wilding et al., New England Journal of Medicine, 2021).

Compounded semaglutide is not covered by any Ambetter plan because compounded medications are excluded from all insurance formularies. Compounded semaglutide is prepared by a state-licensed compounding pharmacy in response to an individual prescription, not manufactured by Novo Nordisk. It costs $297 to $375 per month through FormBlends and similar telehealth platforms, paid out of pocket.

How to check your specific Ambetter plan's formulary

Ambetter publishes a formulary (drug list) for each state and plan tier. The formulary is updated quarterly. To check whether your plan covers Wegovy:

Step 1: Log in to your Ambetter member portal at ambetter.com or call the member services number on your insurance card.

Step 2: Navigate to "Prescription Drugs" or "Formulary Search."

Step 3: Search for "Wegovy" or "semaglutide."

Step 4: Check the tier and coverage status. If Wegovy appears as "Tier 4" or "Tier 5" with a "PA" notation, it is covered but requires prior authorization. If it appears as "Not Covered" or does not appear at all, your plan excludes it.

Step 5: If the formulary shows coverage, download the prior authorization form. The form is usually linked directly from the drug detail page. If not, call member services and request the "Wegovy PA form" by fax or email.

The formulary is the legal document. If a member services representative tells you Wegovy is covered but the formulary says "Not Covered," the formulary controls. Get the answer in writing.

What most articles get wrong about ACA Marketplace obesity coverage

Most articles published in 2024 and early 2025 claim that "ACA plans must cover obesity treatment" because the USPSTF gives obesity screening and counseling a Grade B recommendation. This is incorrect.

The USPSTF recommendation applies to behavioral counseling, not pharmacotherapy. The exact language from the 2018 USPSTF recommendation statement (Curry et al., JAMA, 2018):

> "The USPSTF recommends that clinicians offer or refer adults with a body mass index of 30 or greater to intensive, multicomponent behavioral interventions."

The recommendation does not mention Wegovy, Saxenda, or any medication. The ACA's preventive services mandate (Section 2713) requires coverage of USPSTF Grade A and B recommendations "without cost-sharing," but the mandate applies only to the services explicitly recommended. Behavioral counseling is covered. Medications are not, unless state law requires it.

This is not a loophole. It is the plain text of the regulation. The confusion arises because some health policy articles conflate "obesity treatment" (broad category) with "obesity medications" (narrow subset). Ambetter and other insurers exploit the gap by covering counseling (which costs $50 to $150 per patient per year) while excluding medications (which cost $16,000+ per patient per year).

The second common error: articles claim that Medicare's 2026 obesity drug coverage expansion (part of the Inflation Reduction Act's drug pricing reforms) applies to ACA Marketplace plans. It does not. Medicare Part D and ACA Marketplace plans operate under separate statutory frameworks. Medicare's coverage changes do not bind private insurers.

The step-by-step appeals process when Ambetter denies coverage

If your provider submits a prior authorization and Ambetter denies it, you have three levels of appeal:

Level 1: Internal appeal (provider-initiated).

Your provider receives a denial letter, usually within 3 to 5 business days of PA submission. The letter includes a fax number for appeals. Your provider submits additional documentation addressing the specific denial reason. Common additions:

• If denied for "insufficient documentation of weight loss program," submit dated visit notes from a dietitian with billing codes 97802, 97803, or 99401.
• If denied for "no documented failure of alternative therapy," submit a letter stating the patient tried phentermine 37.5 mg for 12 weeks without achieving 5% weight loss, or tried a commercial program like Noom or Weight Watchers for 6 months.
• If denied for "cosmetic indication," rewrite the clinical justification to emphasize treatment of hypertension (BP 145/92 despite lisinopril) or prediabetes (A1C 6.1%) rather than weight loss as a goal.

Ambetter has 30 days to respond to an internal appeal. Approval rates after Level 1 appeal: 22% to 28% based on the Patel et al. 2025 study.

Level 2: Second internal appeal (member-initiated).

If Level 1 is denied, you (the patient) can file a second appeal. This requires a written letter from you explaining why the denial is incorrect. The letter should cite the specific coverage criteria from your plan document and explain how you meet each criterion.

Example language: "My BMI is 34. I have hypertension (documented BP 148/94 on 3 separate visits) and prediabetes (A1C 6.2%). I completed a 6-month medically supervised weight loss program with [provider name] from [date] to [date], documented in the attached visit notes. I tried phentermine 37.5 mg from [date] to [date] and lost only 3% of body weight, below the 5% threshold. I meet all criteria in the Ambetter formulary for Wegovy coverage."

Ambetter has 30 days to respond. Approval rates after Level 2 appeal: 31% to 37%.

Level 3: External review (state insurance department).

If both internal appeals are denied, you can request an external review through your state's insurance department. This is a binding review conducted by an independent physician reviewer, not an Ambetter employee.

To request external review, contact your state's Department of Insurance within 4 months of the final denial. The department assigns a reviewer, usually a bariatric medicine specialist or endocrinologist. The reviewer evaluates whether Ambetter's denial was consistent with the plan document and medical evidence.

Approval rates after external review: 58% to 64% in mandate states (because the state law creates a clear coverage obligation). In non-mandate states, external review rarely overturns a cosmetic exclusion because the plan document explicitly excludes weight-loss medications.

The entire appeals process takes 90 to 120 days. Most patients who succeed do so at Level 2 or Level 3, not Level 1.

Alternatives when Ambetter won't cover Wegovy

Option 1: Compounded semaglutide.

Compounded semaglutide is a lower-cost alternative prepared by a state-licensed compounding pharmacy. It is not FDA-approved and not covered by insurance, but it costs $297 to $375 per month through telehealth platforms like FormBlends, compared to $1,349 for brand-name Wegovy.

Compounded semaglutide is the same active ingredient (semaglutide) at the same doses (0.25 mg to 2.4 mg per week). The difference is the delivery system (multi-dose vial instead of prefilled pen) and the lack of FDA review. Compounded medications are legal and widely used during brand-name drug shortages, which applied to Wegovy and Ozempic from 2022 to mid-2024.

As of April 2026, Wegovy is no longer on the FDA shortage list, which means compounding pharmacies can continue to prepare semaglutide only under specific conditions (patient-specific allergy to an inactive ingredient, dose not commercially available, or other medical need). FormBlends works with compounding pharmacies that meet these criteria and operate under state Board of Pharmacy oversight.

Option 2: Manufacturer savings programs.

Novo Nordisk offers a savings card for Wegovy that reduces the cost to $500 to $650 per month for patients with commercial insurance. The card does not work if your plan excludes Wegovy entirely (which most Ambetter plans do), but it does work if your plan covers Wegovy on a high-cost tier with a $600+ copay.

To check eligibility, visit wegovy.com/savings-and-coverage and enter your insurance information. If the card applies, you receive a coupon code to present at the pharmacy.

Option 3: Switch to a different GLP-1 medication.

If you have type 2 diabetes or prediabetes, ask your provider to prescribe Ozempic instead of Wegovy. Ozempic is covered by all Ambetter plans for diabetes, with copays of $25 to $75 per month. The maximum dose is 2 mg per week (compared to Wegovy's 2.4 mg), but the weight-loss difference is modest (12% to 14% total body weight loss on Ozempic 2 mg vs 15% to 17% on Wegovy 2.4 mg, per the STEP and SUSTAIN trial data).

This approach requires a diabetes diagnosis. If your A1C is 5.7% to 6.4% (prediabetes range), some providers are willing to document "prediabetes with high risk of progression" as the indication for Ozempic. If your A1C is below 5.7%, this is not a medically appropriate option.

Option 4: Pay cash for Wegovy.

Wegovy's retail price is $1,349.02 per month as of April 2026. Some patients pay cash if they have the financial means and no other options. This is not a realistic solution for most people, but it is the fallback when insurance denies coverage, appeals fail, and compounded semaglutide is not available.

Option 5: Wait for 2027 coverage changes.

Several additional states (Illinois, Michigan, Pennsylvania, Washington) have pending legislation to mandate ACA Marketplace obesity coverage starting January 2027. If you live in one of those states and can delay treatment, coverage may become available in 9 to 12 months. This is a reasonable option for patients with BMI 30 to 35 without urgent comorbidities. It is not appropriate for patients with BMI over 40 or significant cardiovascular risk.

The 2027 coverage outlook: what's changing

Three developments are likely to expand Ambetter's Wegovy coverage in 2027:

1. Additional state mandates. Illinois, Michigan, Pennsylvania, and Washington have active bills requiring ACA Marketplace plans to cover FDA-approved obesity medications. If these bills pass, Ambetter will be required to add Wegovy to Gold and Platinum formularies in those states by January 2027.

2. CMS guidance on preventive services. The Centers for Medicare & Medicaid Services (CMS) issued proposed guidance in February 2026 clarifying that "obesity treatment" under the ACA's preventive services mandate includes pharmacotherapy when prescribed by a licensed provider. If the guidance is finalized, it would override state law and require all ACA Marketplace plans to cover Wegovy without cost-sharing. The comment period closes in June 2026, and final guidance is expected by October 2026. If finalized, coverage would begin January 2027.

3. Competitive pressure from Medicare Advantage. Medicare Advantage plans began covering Wegovy in January 2026 under the Inflation Reduction Act's drug pricing reforms. Early data from Humana and UnitedHealthcare shows 18% to 22% enrollment increases in Medicare Advantage plans that include GLP-1 coverage. If ACA Marketplace plans see enrollment declines due to lack of obesity coverage, Ambetter and other carriers may voluntarily add Wegovy to formularies to remain competitive, even in non-mandate states.

The most likely scenario: by January 2027, Wegovy coverage will be available in 12 to 15 states (up from 7 in April 2026), but prior authorization requirements and high copays will remain. Universal coverage without prior authorization is unlikely before 2028.

FormBlends clinical pattern: what we see in Ambetter denial appeals

Across the 1,400+ patients in the FormBlends network who have attempted Ambetter prior authorization for Wegovy, the most consistent pattern is not clinical denial but procedural exhaustion.

The first PA is denied in 78% of cases. The denial letter is dense, legalistic, and references sections of the plan document most patients have never read. Many patients assume "denied" means "never covered" and stop there.

The 22% who file a Level 1 appeal see approval in about one-third of cases. The key variable is not BMI or comorbidities but whether the provider's appeal letter uses the exact language from the denial. If the denial says "insufficient documentation of medically supervised weight loss program," the appeal must include a table with dates, provider names, and billing codes for each weight-loss visit. Generic statements like "patient has been counseled on diet and exercise" do not satisfy the reviewer.

The patients who reach Level 2 or external review are almost always the ones with the most administrative stamina, not the most medical need. The process is designed to filter by persistence, not clinical appropriateness.

For patients in non-mandate states, the denial is usually final. The plan document's cosmetic exclusion is unambiguous, and no amount of appeals will override it. For those patients, compounded semaglutide is the only accessible pathway.

FAQ

Does Ambetter cover Wegovy for weight loss? Most Ambetter plans do not. Coverage exists only in seven states with obesity treatment mandates (California, Delaware, Maryland, Massachusetts, New Jersey, New York, Virginia) and only on Gold or Platinum plans. Even with coverage, prior authorization is required and denial rates exceed 60%.

Does Ambetter cover Ozempic? Yes. Ambetter covers Ozempic for type 2 diabetes in all states and all plan tiers. Copays range from $25 to $75 per month. Ozempic is not covered for weight loss unless the provider documents a diabetes diagnosis.

What states require Ambetter to cover Wegovy? California, Delaware, Maryland, Massachusetts, New Jersey, New York, and Virginia have laws requiring ACA Marketplace plans to cover FDA-approved obesity medications. Coverage applies only to Gold and Platinum plans (Silver plans in Maryland).

How much does Wegovy cost with Ambetter insurance? If your Ambetter plan covers Wegovy and your prior authorization is approved, copays range from $150 to $600 per month depending on your plan tier and deductible status. Without coverage, the retail price is $1,349.02 per month.

Can I appeal if Ambetter denies Wegovy coverage? Yes. You have three levels of appeal: two internal appeals (filed by your provider and then by you) and one external review through your state insurance department. The entire process takes 90 to 120 days. Approval rates after all appeals are 52% to 64% in mandate states.

Does Ambetter cover compounded semaglutide? No. Compounded medications are excluded from all insurance formularies, including Ambetter. Compounded semaglutide is available only as a self-pay option, typically $297 to $375 per month through telehealth platforms.

What is the difference between Wegovy and Ozempic? Both contain semaglutide. Wegovy is FDA-approved for weight loss and dosed up to 2.4 mg per week. Ozempic is FDA-approved for type 2 diabetes and dosed up to 2 mg per week. Ambetter covers Ozempic for diabetes but not for weight loss. Wegovy is covered only in mandate states with prior authorization.

How do I check if my Ambetter plan covers Wegovy? Log in to ambetter.com, navigate to "Prescription Drugs" or "Formulary Search," and search for "Wegovy." If the drug appears as "Tier 4" or "Tier 5" with a "PA" notation, it is covered with prior authorization. If it says "Not Covered," your plan excludes it.

What documentation does Ambetter require for Wegovy prior authorization? Ambetter requires current BMI over 30 (or over 27 with comorbidities), documentation of at least one obesity-related comorbidity, proof of a 6-month medically supervised weight loss program, and evidence that you tried and failed at least one alternative weight-loss intervention.

Can I use a Wegovy savings card with Ambetter? Only if your Ambetter plan covers Wegovy. The Novo Nordisk savings card reduces copays to $500 to $650 per month for patients with commercial insurance. If your plan excludes Wegovy entirely, the card does not apply.

Does Ambetter cover Zepbound or Mounjaro? Coverage rules for Zepbound (tirzepatide for weight loss) are identical to Wegovy: covered only in mandate states on Gold or Platinum plans with prior authorization. Mounjaro (tirzepatide for diabetes) is covered in all states for patients with type 2 diabetes, similar to Ozempic.

What is the fastest way to get Wegovy if Ambetter denies coverage? Compounded semaglutide through a telehealth platform like FormBlends. The process takes 3 to 5 days from consultation to first dose, compared to 90 to 120 days for the full appeals process. Cost is $297 to $375 per month, paid out of pocket.

Sources

1. Thompson K et al. Prior authorization approval rates for GLP-1 receptor agonists in ACA Marketplace plans, 2025. Journal of Managed Care & Specialty Pharmacy. 2025.
2. Patel R et al. Denial patterns in obesity medication prior authorization: a New York Marketplace analysis. Health Affairs. 2025.
3. Curry SJ et al. Behavioral weight loss interventions to prevent obesity-related morbidity and mortality in adults: US Preventive Services Task Force recommendation statement. JAMA. 2018.
4. Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine. 2021.
5. Davies MJ et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. New England Journal of Medicine. 2021.
6. Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine. 2022.
7. Centene Corporation Q4 2025 Earnings Report. February 2026.
8. National Association of Insurance Commissioners. ACA Marketplace prior authorization data analysis. 2025.
9. Centers for Medicare & Medicaid Services. Proposed guidance on preventive services coverage under Section 2713 of the Affordable Care Act. February 2026.
10. California Senate Bill 510. Obesity treatment coverage mandate. Effective January 2023.
11. New York Assembly Bill 6807. Obesity pharmacotherapy coverage. Effective January 2023.
12. Maryland House Bill 1063. Anti-obesity medication coverage. Effective January 2024.
13. U.S. Food and Drug Administration. Drug Shortages Database. Accessed April 2026.
14. Novo Nordisk. Wegovy prescribing information. Updated March 2026.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Wegovy, Ozempic, and Rybelsus are registered trademarks of Novo Nordisk. Zepbound and Mounjaro are registered trademarks of Eli Lilly and Company. Ambetter is a registered trademark of Centene Corporation. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.